Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$16.26 +2.7%	$12.38	$9.22 ▼ $21.00	$748.16M	1	1.95 million shs	1.00 million shs
BBNX Beta Bionics	$17.05 +0.9%	$15.14	$8.89 ▼ $24.50	$741.17M	N/A	811,054 shs	892,018 shs
INFU InfuSystem	$9.57 -0.4%	$6.79	$4.61 ▼ $9.97	$196.29M	1.81	168,396 shs	167,703 shs
TNDM Tandem Diabetes Care	$11.93 +8.0%	$15.58	$9.98 ▼ $47.60	$806.10M	1.46	2.82 million shs	2.19 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	0.00%	+8.91%	+23.09%	+46.88%	+25.85%
BBNX Beta Bionics	0.00%	+0.06%	+18.16%	+18.16%	+1,704,999,900.00%
INFU InfuSystem	0.00%	-0.62%	+61.93%	+76.89%	+38.70%
TNDM Tandem Diabetes Care	0.00%	+10.26%	-22.73%	-42.42%	-72.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.7482 of 5 stars	3.5	2.0	0.0	3.3	1.7	0.6
BBNX Beta Bionics	2.606 of 5 stars	4.4	0.0	0.0	2.5	0.8	0.0
INFU InfuSystem	3.5234 of 5 stars	2.0	5.0	0.0	2.9	4.2	1.9
TNDM Tandem Diabetes Care	4.647 of 5 stars	4.1	3.0	4.9	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$26.00	59.90% Upside
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	32.29% Upside
INFU InfuSystem	4.00	Strong Buy	$12.50	30.62% Upside
TNDM Tandem Diabetes Care	2.27	Hold	$22.47	88.32% Upside

Current Analyst Ratings Breakdown

Latest INFU, BBNX, TNDM, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$10.35 ➝ $11.00
8/11/2025	TNDM Tandem Diabetes Care	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $12.00
8/8/2025	TNDM Tandem Diabetes Care	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$53.00 ➝ $51.00
8/7/2025	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$59.00 ➝ $24.00
8/7/2025	TNDM Tandem Diabetes Care	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $14.00
8/7/2025	TNDM Tandem Diabetes Care	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$20.00 ➝ $17.00
8/7/2025	TNDM Tandem Diabetes Care	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $13.00
8/7/2025	TNDM Tandem Diabetes Care	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $25.00
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$187.34M	3.99	N/A	N/A	$2.36 per share	6.89
BBNX Beta Bionics	$65.12M	11.38	N/A	N/A	($5.72) per share	-2.98
INFU InfuSystem	$139.89M	1.40	$0.75 per share	12.79	$2.47 per share	3.87
TNDM Tandem Diabetes Care	$940.20M	0.86	N/A	N/A	$4.01 per share	2.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.10	N/A	N/A	N/A	-2.29%	-4.43%	-2.34%	11/6/2025 (Estimated)
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	$870K	$0.23	159.53	30.87	N/A	1.12%	2.78%	1.41%	N/A
TNDM Tandem Diabetes Care	-$96.03M	-$3.09	N/A	N/A	N/A	-20.51%	-65.40%	-13.87%	11/5/2025 (Estimated)

Latest INFU, BBNX, TNDM, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	-$0.48	-$0.08	-$0.78	$238.39 million	$240.68 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.59	4.14	2.67
BBNX Beta Bionics	N/A	14.68	13.79
INFU InfuSystem	0.50	1.98	1.59
TNDM Tandem Diabetes Care	2.32	2.44	1.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
BBNX Beta Bionics	N/A
INFU InfuSystem	71.13%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
BBNX Beta Bionics	N/A
INFU InfuSystem	11.40%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	46.01 million	44.73 million	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
TNDM Tandem Diabetes Care	2,650	67.57 million	66.29 million	Optionable

INFU, BBNX, TNDM, and AXGN Headlines

Recent News About These Companies

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.4% Following Analyst Upgrade

August 24 at 2:19 AM | americanbankingnews.com

Tandem Diabetes Care Inc News (TNDM) - Investing.com

August 23 at 12:32 AM | investing.com

Tandem Diabetes Care, Inc. $TNDM Shares Purchased by Aberdeen Group plc

August 23 at 4:34 AM | marketbeat.com

Vanguard Group Inc. Reduces Holdings in Tandem Diabetes Care, Inc. $TNDM

August 23 at 3:35 AM | marketbeat.com

Tandem Diabetes Care (TNDM) Gets a Buy from RBC Capital

August 22 at 10:47 PM | theglobeandmail.com

Versor Investments LP Buys Shares of 30,500 Tandem Diabetes Care, Inc. $TNDM

August 22 at 4:44 AM | marketbeat.com

Algert Global LLC Purchases 119,784 Shares of Tandem Diabetes Care, Inc. $TNDM

August 22 at 4:43 AM | marketbeat.com

Citigroup Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $11.00

August 22 at 2:51 AM | americanbankingnews.com

Public Sector Pension Investment Board Raises Stock Position in Tandem Diabetes Care, Inc. $TNDM

August 19, 2025 | marketbeat.com

Sector Gamma AS Acquires New Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

August 17, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by Brokerages

August 15, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14, 2025 | tmcnet.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. ...

August 14, 2025 | gurufocus.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 14, 2025 | businesswire.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...

August 14, 2025 | gurufocus.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14, 2025 | businesswire.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts

August 14, 2025 | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Cut to "Hold" at Lake Street Capital

August 14, 2025 | americanbankingnews.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 13, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up Following Insider Buying Activity

August 13, 2025 | marketbeat.com

5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call

August 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU, BBNX, TNDM, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$16.26 +0.42 (+2.65%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$16.39 +0.13 (+0.77%)

As of 08/22/2025 07:22 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Beta Bionics NASDAQ:BBNX

$17.05 +0.16 (+0.95%)

As of 08/22/2025 04:00 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

InfuSystem NYSE:INFU

$9.57 -0.04 (-0.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.57 0.00 (0.00%)

As of 08/22/2025 05:40 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Tandem Diabetes Care NASDAQ:TNDM

$11.93 +0.88 (+7.96%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.89 -0.04 (-0.34%)

As of 08/22/2025 06:31 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time